|
A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients Clinical research trials and A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients. A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients clinical trial. Subjects often receive the most expert healthcare possible for their A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients  A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients
A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients
For Condition: HIV Infections
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: The purpose of this study is to see if giving 1592U89 to HIV-infected patients is safe and effective in lowering viral load (level of HIV in the blood) and raising the level of CD4 cells (cells of the body that help fight infection).
Details: Patients are randomized to receive one of three doses of 1592U89. During this randomized dosing phase, if a patient meets one of the following criteria, he/she is offered open-label 1592U89 (300 mg) plus zidovudine (ZDV) plus lamivudine (3TC) (or other licensed antiretrovirals according to standard practice). Criteria are based on falling CD4 counts (return to baseline on two occasions at least 1 month apart), disease progression (defined as occurrence of a new AIDS-defining event according to CDC classification excluding CD4 counts less than 200 cells/mm3), or lack of virus suppression (defined as less than 0.7log10 reduction in viral load at Week 4 with a repeat value 1 week later, more than 5000 copies/ml HIV RNA at Weeks 12, 16, 20, or 24, or 5000 copies/ml or more anytime after Week 24).
Eligibility:
Study Type: Interventional, Treatment, Double-Blind
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria:
Total Enrollment:
Location and Contact Information:
Hopital de Purpan / Service du Professeur Auvergnat
Toulouse Cedex, ,
France
Universitatsklinikurn Frankfurt
Frankfurt, ,
Germany
Universitat Erlangen
Erlangen, ,
Germany
Group Hospier Pitie-Salpetriere / Maladies Infec et Trop
Paris Cedex 13, ,
France
Groupe Hospitalier Bichat-Claude Bernard
Paris Cedex 18, ,
France
Hopital de Purpan / CHU de Rangueil / Medecine Interue
Toulouse Cedex, ,
France
Additional Information:
Study ID Numbers: 238H; CNAB2002
Study Start Date:
Record last reviewed: August 1997
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002390
Other Hiv Infections Studies:
1. A Double-Blind, Randomized Parallel Group Study Comparing Procysteine to Placebo in HIV-Infected Patients Who Are Taking Antiretroviral Nucleosides
2. A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients
3. The Safety of Four Different Dose Levels of Wobenzym in HIV-Positive Patients
4. Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals
5. A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines
Related Studies:
Other HIV Infections Clinical Trials
Other Clinical Trials
Other Toulouse Cedex Clinical Trials
A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients
|
|
|
|
|
|
|
|
